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Modulation of the Renal Response to ACE Inhibition
by ACE Insertion/Deletion Polymorphism During
Hyperglycemia in Normotensive, Normoalbuminuric
Type 1 Diabetic Patients
Laurent Weekers,1 Be´atrice Bouhanick,2 Samy Hadjadj,3,4 Yves Gallois,5 Ronen Roussel,6,7
Franck Pean,7 Amos Ankotche,6 Gilles Chatellier,8 Franc¸ois Alhenc-Gelas,9 Pierre J. Lefebvre,1
and Michel Marre6,7
ACE inhibition protects kidney function, but ACE insertion/
deletion (I/D) polymorphism affects renal prognosis in type 1
diabetic patients. ACE genotype may influence the renal
benefits of ACE inhibition. We studied the impact of ACE I/D
polymorphism on the renal hemodynamic changes induced by
ACE inhibition in type 1 diabetes. We studied renal hemody-
namics (glomerular filtration rate [GFR], effective renal
plasma flow [ERPF], filtration fraction [GFR/ERPF], mean
arterial pressure [MAP], and total renal resistances [MAP/
ERPF]) repeatedly during normoglycemia and then hypergly-
cemia in 12 normotensive, normoalbuminuric type 1 diabetes
and the II genotype (associated with nephroprotection)
versus 22 age- and sex-matched subjects with the ACE D
allele after three randomly allocated 2- to 6-week periods
on placebo, 1.25 mg/day ramipril, and 5 mg/day ramipril in a
double-blind, cross-over study. During normoglycemia, the
hemodynamic changes induced by ramipril were similar in
both genotypes. During hyperglycemia, the changes in-
duced by ramipril were accentuated in the II genotype
group and attenuated dose dependently in the D allele
group (treatment-genotype interaction P values for ERPF,
0.018; MAP, 0.018; and total renal resistances, 0.055).
These results provide a basis to different renal responses
to ACE inhibition according to ACE genotype in type 1
diabetes.Diabetes 54:2961–2967, 2005
The cardiovascular and vital prognoses of type 1diabetic patients are conditioned by their renalstatus (1). The glomerular hypertension respon-sible for diabetic nephropathy results from an
interaction between preglomerular capillary vasodilata-
tion provoked by hyperglycemia and individual postglo-
merular resistances (2). These resistances depend on
vasoconstriction due to angiotensin 2 (3). The intrarenal
production of angiotensin 2 from angiotensin 1 depends on
the availability of ACE. ACE activity can be modulated
pharmacologically by ACE inhibitors and genetically by a
267-bp insertion/deletion (I/D) polymorphism in intron 16
of the ACE gene (4). ACE inhibition can prevent or slow
the progression of diabetic nephropathy (5–7). The ACE II
genotype (the genotype associated with the lowest ACE
levels) is associated with a reduced risk of diabetic
nephropathy in type 1 diabetes (8–10).
The effect of ACE I/D polymorphism on the benefits
obtained with ACE inhibition in terms of kidney function
in patients with type 1 diabetes is therefore an important
issue. In one study on proteinuric type 1 diabetic patients,
the ACE DD genotype was found to be associated with a
more rapid decrease in glomerular filtration rate (GFR) on
captopril (11). In another study, on normo- or microalbu-
minuric, normotensive type 1 diabetic patients, the II
genotype was associated with a more rapid decrease in
urinary albumin excretion (UAE) on lisinopril (12). How-
ever, the mechanisms by which the ACE I/D polymor-
phism affects renal response to ACE inhibition remain
unclear.
In this study, we investigated whether the renal hemo-
dynamic changes induced by high glucose concentrations
during ACE inhibition differ in type 1 diabetic patients with
the ACE II genotype and in those with the ACE D allele.
We studied renal hemodynamic responses to graded doses
of ramipril (an ACE inhibitor) in normotensive, nor-
moalbuminuric type 1 diabetic patients selected on the
basis of ACE genotype. During this proof-of-concept study,
we investigated renal hemodynamics in conditions of
normo- and hyperglycemia, because hyperglycemia causes
glomerular capillary hypertension, which leads to ne-
phropathy (13), and because we could relate these
changes to ACE I/D genotypes (14).
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RESEARCH DESIGN AND METHODS
The participants were selected from type 1 diabetic patients attending the
Diabetic Clinic of Angers University Hospital (France). The inclusion criteria
were age of 50 years; men or women with mechanical contraception; onset
of type 1 diabetes before the age of 35 years; normal blood pressure (140/80
mmHg); normal UAE (30 mg/24 h); no proliferative retinopathy; no chronic
disease other than type 1 diabetes; and no treatment other than insulin. We
asked patients to consent to genotyping for ACE I/D polymorphism. Those
selected as case subjects or control subjects were then asked to participate in
the study described below. For ethical reasons, none of the patients were
informed of their own ACE genotype. The study protocol was reviewed by the
local ethics committee, and all patients gave written informed consent.
The patients selected as case subjects had the II genotype. Each case
subject was matched with two control subjects carrying the D allele for age
(5 years), sex, and diabetes duration (5 years), because several cross-
sectional studies (15–17) and follow-up studies (8–10) have shown that the
ACE D allele has a dominant effect on the risk for nephropathy.
We compared two doses of ramipril, a low dose (1.25 mg/day) and the usual
dose (5 mg/day), with placebo in a randomized, double-blind, cross-over
experiment. Study drugs were given once per day in the morning, for
treatment periods of 2–6 weeks, separated by 4-week washout periods. The
doses of ramipril used were chosen based on previous studies (18,19). The
durations of the minimal treatment period (2 weeks) and of the washout
period (4 weeks) were selected based on previous studies, to ensure steady
ACE inhibition and the absence of carry-over effects (20). At the end of each
treatment period, we investigated renal hemodynamics in the patients and the
changes in renal hemodynamics induced by hyperglycemia, as described
below.
Determinations. The protocol used for renal hemodynamic studies has been
described elsewhere (14). Briefly, participants were admitted to the center for
clinical investigations the evening before the study. They were asked to collect
their urine during the 24 h before admission and to bring it to the hospital with
them for urinary sodium and albumin measurements. Patients ate their
evening meal at the hospital, and their regular dose of insulin was adminis-
tered subcutaneously. They received an intravenous infusion of regular insulin
overnight, according to a published algorithm (21). At 7 A.M., blood was
sampled from patients in the supine position for the determination of serum
ACE activity, plasma active renin and aldosterone levels, and HbA1c (A1C).
They were then given tablets corresponding to the placebo or ramipril and
asked to drink tap water regularly thereafter to obtain forced diuresis of
10–15 ml/min. Once diuresis was established, a primed intravenous infusion
of 125I-iodothalamate and 131I-labeled hippurate was initiated. This infusion
was continued throughout testing. Thus, the tracer clearances were calculated
from their urine concentrations divided by their plasma concentrations,
multiplied by urine flow. There were six consecutive 30-min clearance
periods. During the first three periods, the morning insulin infusion rate was
kept constant, such that plasma glucose concentration remained close to
normal (5 mmol/l, “normoglycemia” period). We then infused exogenous
glucose for 10 min to achieve high blood glucose levels, while keeping the
insulin infusion rate constant, for the remaining three 30-min clearance
periods (15 mmol/l, “hyperglycemia” period).
The renal clearance of 125I-iodothalamate was assumed to be equal to GFR
and that of 131I-labeled hippurate to effective renal plasma flow (ERPF). The
ERPF value was not corrected for renal hippurate extraction, because it has
been reported that ACE inhibition does not affect renal extraction coefficients
in a given individual (22). Mean arterial pressure (MAP) was measured
automatically (Dinamap, Critikon, FL) every 5 min, and values were averaged
for each clearance period. We calculated filtration fraction by dividing GFR by
ERPF. Total renal resistances (TRRs) were calculated by dividing MAP by
ERPF. The renal hemodynamics values for the normoglycemia period were
calculated as a mean of the values for the second and third clearance periods,
and those of the hyperglycemia period were calculated as a mean of the values
for the fifth and sixth clearance periods (14). In our laboratory, the intraindi-
vidual coefficient of variations were 5  1, 7  1, and 2  1% for GFR, ERPF,
and MAP, respectively (obtained from nine type 1 diabetic subjects).
Serum ACE activities were measured enzymatically (23), plasma active
renin was determined by immunoradiometry (24), plasma aldosterone con-
centration by radioimmunoassay (25), plasma glucose concentration by
enzymatic assay, and A1C levels by high-performance liquid chromatography
(Diamat; Bio-Rad, Ivry-sur-Seine, France). Urinary albumin and sodium con-
centrations were measured by nephelometry (26) and flame spectrometry,
respectively.
Statistical analysis. Results are presented as means  1 SD or median
(range). Because no previous study was available for power calculation, we
used previously observed differences in renal hemodynamics during hypergly-
cemia between II and non-II patients (14). Taking an -risk of 5% and a -risk
of 90%, we would need 12 case subjects to show a difference in TRR. For
technical reasons, assessments were not completed in two patients with the D
allele. We therefore present results for 12 case subjects with the II genotype
and 22 control subjects. We used nonparametric tests to analyze the global
effects of genotype (Mann-Whitney U test), of ramipril dose (Kruskal-Wallis),
and of their interaction (Mantel-Haenszel test). We separately tested, within
each genotype, the dose dependence of the effect of ramipril (Kruskal-Wallis),
and, within each ramipril dose, the genotype effect (Mann-Whitney U test).
RESULTS
Baseline characteristics of the participants. The par-
ticipants’ characteristics are given in Table 1. No differ-
ences according to genotype were observed. Baseline
BMIs and A1C levels were similar at the start of each
treatment period and at the time of the renal hemodynam-
ics study (data not shown). The urinary sodium excretions
were 149  35 for the II participants vs. 162  36 mmol/24
h for the non-II ones at baseline (NS); they remained not
different with 1.25 mg/day ramipril (146  65 vs. 165  40
mmol/24 h) and 5 mg/day ramipril (161  50 vs. 163  35
mmol/24 h). However, UAE values were lower for II
participants than for D allele carriers at baseline: 3 mg/24 h
(range 2–4) vs. 6 (2–23); P  0.0052. These UAE values
were reduced to 3 mg/24 h (2–24) in the II patients and to
3 mg/24 h (2–19) in the non-II patients by treatment with
1.25 mg/day ramipril. UAE values of 3 mg/24 h (2–6) were
recorded in the II participants on 5 mg/day ramipril versus
3 mg/24 h (2–71) in the D allele carriers. No order effect
was observed in this cross-over study for these results or
for any of the variables analyzed below.
Changes in serum ACE activity and plasma active
renin and aldosterone levels (Table 2). Baseline serum
ACE activities were lower in the II participants than in the
others. Ramipril treatment had a strong effect on plasma
ACE concentration, regardless of genotype. This effect
was observed with the lower dose of ramipril in all groups.
Plasma active renin levels were similar in both groups at
baseline. They rose very significantly on ramipril treat-
ment (P 0.0001); plasma active renin levels were slightly
lower in II patients than in patients with the D allele for
treatment with 5 mg/day ramipril. Plasma aldosterone
levels were similar in all groups; they were not affected by
treatment, genotype, or treatment  genotype interaction.
Kidney function during renal hemodynamics study
(Table 3)
Changes induced by treatments during normoglyce-
mia (Table 3, left panel). At baseline, kidney function
during normoglycemia was similar in the two groups. GFR
was not affected by genotype, treatment dose, or their
interaction. ERPF increased slightly with ramipril dose,
independently of genotype. The filtration fraction de-
TABLE 1
Clinical and biological characteristics of the study participants,
at baseline
Genotype (n) II (12) non-II (22) P
Age (years) 30 (7) 31 (6) NS
Sex (men/women) 6/6 11/11 NS
Diabetes duration
(years) 12.0 9.3 14.4 5.9 NS
BMI (kg/m2) 23.6 2.6 23.6 3.5 NS
A1C (%) 8.3 1.1 8.7 1.0 NS
SBP (mmHg) 123 14 118 10 NS
DBP (mmHg) 66 9 66  7 NS
Data are means  SD. DBP, diastolic blood pressure; SBP, systolic
blood pressure.
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creased (P  0.0130) with increasing ramipril dose, with
no effect of genotype. There was no interaction between
genotype and treatment. MAP was reduced by treatment,
but not significantly so. Baseline TRR values did not differ
according to genotype. TRR decreased significantly on
ramipril treatment (P  0.030); this response was geno-
type independent.
Hyperglycemia-induced changes according to treat-
ment and genotype (Table 3, right panel and Fig. 1).
Changes in GFR during hyperglycemia were not signifi-
cantly affected by treatment dose or genotype, and no
genotype-treatment interaction was observed. Conversely,
the increase in ERPF during hyperglycemia seen in the II
participants was potentiated by ramipril, whereas it was
attenuated in the non-II participants (P  0.018 for treat-
ment-genotype interaction). No significant change in filtra-
tion fraction was seen during hyperglycemia, regardless of
treatment, genotype, or their interaction.
MAP decreased in the II participants, but not in the
non-II participants, during hyperglycemia. This difference
in MAP response was exacerbated by increasing the dose
of ramipril (P  0.0342 for the genotype effect, P  0.0749
for the treatment effect, P  0.018 for treatment-genotype
interaction). Hyperglycemia provoked a decrease in TRR
in the II participants, which was potentiated by ramipril
dose; this was not the case in the non-II participants (P 
0.1058 for the genotype effect, NS for the treatment effect,
and P  0.055 for the genotype-treatment interaction).
DISCUSSION
This study shows that the beneficial effects of ACE inhi-
bition on the renal circulation of type 1 diabetes subjects
depend on ACE I/D polymorphism, during hyperglycemic
surges. After increases in blood glucose levels, individuals
with the ACE II genotype increased their ERPF and
decreased MAP and TRR (variables indicating beneficial
changes in intraglomerular hydraulic pressure [2]) to a
greater extent than those carrying the ACE D allele. These
findings provide a rationale to explain the smaller long-
term renal benefits of ACE inhibition in type 1 diabetic
patients with the ID or DD ACE genotypes than in those
with the II genotype (11,12). In humans, it is not possible
to measure intraglomerular pressures directly. However,
changes in renal hemodynamics can be estimated by
assessing changes in ERPF and MAP and by calculating
TRR.
The maximum dose of ramipril used in this study was 5
mg/day. The ATLANTIS (Alteplase Thrombolysis for Acute
Noninterventional Therapy in Ischemic Stroke) study dem-
onstrated a dose-dependent effect of ramipril on kidney
function in normotensive type 1 diabetic subjects with
microalbuminuria, using the same doses as used here (19).
The GISEN (Gruppo Italiano di Studi Epidemiologici in
Nefrologia) study also demonstrated a nephroprotective
effect of 5 mg/day ramipril (27). A dose of 10 mg/day
ramipril has also been shown to have a cardioprotective
effect (28,29). The renal hemodynamic effects of 10 mg/day
ramipril were not assessed. However, we found that 1.25
mg/day ramipril decreased albuminuria without affecting
cardiovascular outcome (30), suggesting that the renal
effects of ramipril may begin at lower doses than the
cardiovascular effects (30).
Ramipril had a more pronounced hypotensive effect
during hyperglycemia in the participants with the II geno-
type than in the others. This is consistent with previous
findings concerning kidney function and blood pressure in
type 1 diabetic subjects selected on the basis of ACE
genotype, studied during hyperglycemia (31), and during
infusions of angiotensins 1 and 2 (32). During normogly-
cemia, ramipril had a dose-dependent effect on renal
hemodynamics that did not differ with genotype. This is
consistent with the previously reported lack of effect of
the ACE I/D polymorphism on the hypotensive response to
renin inhibition in healthy volunteers (33).
In the II genotype participants, hyperglycemia enhanced
the decrease in intraglomerular pressure due to ACE
inhibition in a dose-dependent fashion. The opposite effect
was seen in participants carrying the ACE D allele: renal
circulatory changes due to ACE inhibition were strictly
similar to those in the II participants during normoglyce-
TABLE 2











ACE activity (units/l) Placebo 18 7 26 10 0.0077
1.25 mg 7 2 10  7 0.1301 0.1349
5 mg 5 2 6  3 NS
Treatment effect (P) 0.0001 0.0001
Global treatment effect 0.0001 NS*
Active renin (pg/ml) Placebo 7.5 3.3 9.0 3.9 NS
1.25 mg 15.1 9.0 17.6 10.1 NS 0.0812
5 mg 16.3 11.6 26.2 14.8 0.0335
Treatment effect (P) 0.0131 0.0001
Global treatment effect 0.0001 NS*
Aldosterone (pg/ml) Placebo 311 167 253 136 NS
1.25 mg 319 178 278 178 NS NS
5 mg 290 176 318 268 NS
Treatment effect (P) NS NS
Global treatment effect NS NS*
Data are means  SD. NS, P  0.20. P values are global effects of genotype (Mann-Whitney U test), of ramipril doses (Kruskal-Wallis), and
of their interaction (Mantel-Haenszel). P values within each genotype: treatment effect (Kruskal-Wallis). P values within each ramipril dose
are genotype effect (Mann-Whitney U test). *P values for interaction.
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mia, but these beneficial changes were attenuated by
increases in plasma glucose levels. How hyperglycemia
interferes with the renal response to ACE inhibition must
be discussed. There is evidence to suggest that the renin-
angiotensin system is highly active during hyperglycemia
in the renal circulation of subjects with type 1 diabetes
(34,35). We and others (14,31,32) have demonstrated that
these renal hemodynamic changes are greater in subjects
carrying the ACE D allele than in those with the II
genotype. Intraglomerular capillary hydraulic pressure,
the main determinant of renal failure (36), is largely
conditioned by interaction between the vasodilatory ef-
fects of nitric oxide (NO) and the vasoconstrictive effects
of angiotensin 2. However, the vasoconstrictive effect of
angiotensin 2 on the arterioles efferent from glomeruli is
detectable even at very low angiotensin 2 concentrations
in experimental conditions (3,37), whereas the NO-depen-
dent vasodilatation of the arterioles afferent to the glomer-
FIG. 1. Hyperglycemia-induced changes in renal hemodynamic variables, according to ACE I/D polymorphism. Data are means, and error bars are
SE. , II patients; f, non-II patients. *Genotype effect (Mann-Whitney U test); **Treatment effect (Kruskal-Wallis); ***treatment-gene
interaction effect (Mantel-Haenszel interaction). A: GFR (*P  NS; **P  0.1367; ***P  0.183). B: ERPF (*P  NS; **P  NS; ***P  0.018).
C: Filtration fraction (FF) (*P  NS; **P  NS; ***P  NS). D: MAP (*P  0.0344; **P  0.075; ***P  0.018). E: TRRs (*P  0.106; **P  NS;
***P  0.055).
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uli is amplified by local angiotensin 2 levels in a dose-
dependent manner (37). This phenomenon may account
for the impact of the ACE D allele on renal circulation in
type 1 diabetes (14,31,32). The well-known endothelial
dysfunction observed in people with diabetes is primarily
explained by a low capacity for NO-dependent vasodilata-
tion (38), as a direct consequence of hyperglycemia (39).
However, chronic ACE inhibition restores NO-mediated
endothelial function in patients with type 1 diabetes (40).
Thus, the beneficial effect of ACE inhibition on intraglo-
merular hydraulic pressure, through the vasodilatation of
the arterioles efferent from glomeruli, may be counterbal-
anced in type 1 diabetic patients by an increase in the
NO-dependent vasodilatation of the arterioles afferent to
glomeruli. In this case, people with type 1 diabetes and the
ACE D allele would not benefit fully from high doses of
ACE inhibitors during periods of hyperglycemia. Con-
versely, those with the ACE II genotype would not be
adversely affected, because their renal circulation param-
eters have already been shown to be insensitive to hyper-
glycemia (14). Finally, ACE inhibition increases the level
of bradykinin, a stimulator of NO release, in addition to
suppression of angiotensin 2 production (41). Unfortu-
nately, changes in angiotensin 2 and bradykinin concen-
trations within the renal circulation cannot be measured in
humans, and the changes in serum ACE activities induced
by low or high doses of ACE inhibitors do not reflect the
actual changes occurring within the vascular wall (42).
We believe our findings to be of clinical relevance. ACE
inhibitors are currently the only evidence-based treatment
for the prevention or treatment of diabetic nephropathy in
patients with type 1 diabetes (5–7). Intensified insulin
treatment is currently recommended for most type 1
diabetic patients (43), and this is supported by the Diabe-
tes Control and Complications Trial (DCCT) and its fol-
low-up studies (44,45). Nonetheless, most individuals with
type 1 diabetes remain hyperglycemic most of the time
(44). The lower efficiency of ACE inhibition in hyperglyce-
mia than in normoglycemia in type 1 diabetic patients with
a high genetic risk for kidney disease is therefore impor-
tant for patient care. Some investigators have suggested
that angiotensin 2 subtype 1 receptor antagonists could be
used to prevent or to treat diabetic nephropathy in type 1
diabetic patients, in conditions in which ACE inhibition is
not feasible (43). Interestingly, the anti-albuminuric effect
of these drugs is independent of ACE I/D polymorphism
(46). However, angiotensin 2 subtype 1 receptor antago-
nists have not been demonstrated to block renal disease in
type 1 diabetes.
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